Sugi Predict

Sugi Predict / Targets / SPNS2

SPNS2

Sphingosine-1-phosphate transporter SPNS2 · Q8IVW8 · SPNS2 on Sugi Atlas →

996 patent compounds predicted against SPNS2, 602 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6285706 SCHEMBL6285706 0.56 2/20
SCHEMBL6287873 SCHEMBL6287873 0.56 2/20
SCHEMBL15960549 SCHEMBL15960549 0.56 2/20
SCHEMBL10779248 SCHEMBL10779248 0.56 2/20
SCHEMBL2957146 SCHEMBL2957146 0.55 2/20
SCHEMBL5285641 SCHEMBL5285641 0.54 2/20
SCHEMBL5291398 SCHEMBL5291398 0.54 2/20
SCHEMBL5291399 SCHEMBL5291399 0.54 2/20
SCHEMBL5291576 SCHEMBL5291576 0.54 2/20
SCHEMBL5291727 SCHEMBL5291727 0.54 2/20
SCHEMBL5292278 SCHEMBL5292278 0.54 2/20
SCHEMBL5295428 SCHEMBL5295428 0.54 2/20
SCHEMBL5301984 SCHEMBL5301984 0.54 2/20
SCHEMBL5304291 SCHEMBL5304291 0.54 2/20
SCHEMBL5304624 SCHEMBL5304624 0.54 2/20
SCHEMBL5305028 SCHEMBL5305028 0.54 2/20
SCHEMBL5813039 SCHEMBL5813039 0.54 2/20
SCHEMBL5813494 SCHEMBL5813494 0.54 2/20
SCHEMBL5816581 SCHEMBL5816581 0.54 2/20
SCHEMBL6282191 SCHEMBL6282191 0.54 2/20

Clinical trials — most relevant to SPNS2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
D-Cycloserine for Serine Palmitoyltransferase Inhibition PHASE4COMPLETED
Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia PHASE2/PHASE3COMPLETED
Hereditary Sensory Neuropathy Serine Trial PHASE2UNKNOWN
PCSK9 Inhibitor Treatment for Patients With SPG5 PHASE1/PHASE2UNKNOWN
Permeability Factor in Focal Segmental Glomerulosclerosis PHASE1/PHASE2COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Consequences of Mutations in the SPG7 Gene at the Heterozygous State nanCOMPLETED
Genetic Regulation of Surfactant Deficiency nanCOMPLETED
Spastic Paraplegia - Centers of Excellence Research Network nanRECRUITING
B Cells in Idiopathic Nephrotic Syndrome nanCOMPLETED
Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy nanCOMPLETED
Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis nanCOMPLETED
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Surfactant Derived Protocol in Heart Failure nanCOMPLETED
Imaging Biomarkers in Spastic Paraplegia Type 5 nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
The Association Between LPCAT1 Genetic Polymorphism and Stress Biomarkers in Neonatal Respiratory Distress Syndrome nanUNKNOWN
Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension nanUNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP) nanCOMPLETED
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
3D-Microscopic Muscle Architecture in Cerebral Palsy nanRECRUITING
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED
Glucose-dependent Asprosin Dynamics nanCOMPLETED
Hydroxychloroquin (HCQ) in chILD of Genetic Defect nanCOMPLETED
Investigation of Biomarkers in Susac Syndrome nanUNKNOWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS) nanCOMPLETED
The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SPNS2 binder may also engage these)

ProteinNameSimilarity
Q91VM4 — 1.000 Q91VM4 →
Q58CV5 — 0.954 Q58CV5 →
Q27963 — 0.952 Q27963 →
Q8TED4 — 0.948 Q8TED4 →
Q1JQC1 — 0.945 Q1JQC1 →
F1NCD6 — 0.945 F1NCD6 →
Q9WU81 — 0.945 Q9WU81 →
Q9H3U5 — 0.944 Q9H3U5 →
Q8BRU6 — 0.944 Q8BRU6 →
Q9H2Y9 — 0.940 Q9H2Y9 →
Q5R8G5 — 0.939 Q5R8G5 →
A6NFX1 — 0.938 A6NFX1 →
SLC16A3 Monocarboxylate transporter 4 0.937 landscape →
SLC18A2 Synaptic vesicular amine transporter 0.935 landscape →
B0JZE1 — 0.935 B0JZE1 →
SLC18A1 Chromaffin granule amine transporter 0.934 landscape →
Q7SY29 — 0.933 Q7SY29 →
Q7Z7J7 — 0.933 Q7Z7J7 →
Q01827 — 0.931 Q01827 →
Q4R766 — 0.930 Q4R766 →
P57787 — 0.930 P57787 →
Q0P5M9 — 0.930 Q0P5M9 →
Q9DC37 — 0.929 Q9DC37 →
Q01818 — 0.929 Q01818 →
O35910 — 0.929 O35910 →
Q7TSY2 — 0.929 Q7TSY2 →
GLS Glutaminase kidney isoform, mitochondrial 0.928 landscape →
ABHD12 Lysophosphatidylserine lipase ABHD12 0.928 landscape →
D3Z7P3 — 0.928 D3Z7P3 →
Q5ZIN0 — 0.927 Q5ZIN0 →